Masanori Furukawa

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

Kosuke Kaji, Norihisa Nishimura, Kenichiro Seki et al. · International Journal of Cancer · 2017 · 247 citations

Medicine, Oncology, Pharmacology +16

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

Kosuke Kaji, Hiroaki Takaya, Soichiro Saikawa et al. · World Journal of Gastroenterology · 2017 · 102 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis

Masanori Furukawa, Kei Moriya, Jiro Nakayama et al. · Hepatology Research · 2020 · 86 citations · Full text

Life Sciences, Microbiology, Pathology +17

Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)

Yasushi Yamasaki, Noriya Uedo, Takuji Akamatsu et al. · Clinical Gastroenterology and Hepatology · 2021 · 50 citations

Medicine, Oncology, Radiology +8

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease

Kazuki Tahara, Takemi Akahane, Tadashi Namisaki et al. · JGH Open · 2019 · 47 citations · Full text

Medicine, Endocrinology, Pathology +16